retatrutide first week Phase III study demonstrates 30% weight loss 🚨Breaking: Retatrutide's first Phase 3

[232][233][234][235] GLP-1 exerts its effect on postprandial glucose concentrations through several mechanisms, including enhancing insulin secretion and suppressing postprandial glucagon secretion in a glucose-dependent manner

This mechanism significantly reduces the risk of hypoglycemia when used alone, though this risk increases when combined with insulin or sulfonylureas

While they reliably support weight reduction, these medications do not specifically preserve muscle mass, emphasizing the importance of combining medication treatment with resistance or weight-bearing exercise to help preserve muscle during the process

The physiology of glucagon-like peptide 1

Each has a similar overall safety profile but may differ in specific side effect frequencies